1 ing the associations between maternal use of folic acid antagonists and these congenital malformation

2 hat evaluated the association between use of folic acid antagonists during the second and third pregn

3 termine whether periconceptional exposure to folic acid antagonists (FAAs) might therefore increase t

4 sis, disruption of purine synthesis with the folic acid antagonist sulfamethoxazole also inhibited sp

5              We compared data on exposure to folic acid antagonists that act as dihydrofolate reducta

6         The case-crossover approach compared folic acid antagonist use between the 2-month embryologi

7                                              Folic acid antagonists, which include such common drugs